Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed Nick Keher Group Chief Financial Officer with effect from 19 March 2019. He will replace Martin Abell, who has resigned and leaves the business on 31 March 2019.
| Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed Nick Keher Group Chief Financial Officer with effect from 19 March 2019. He will replace Martin Abell, who has resigned and leaves the business on 31 March 2019. Nick joins from Royal Bank of Canada (RBC) where he was a Managing Director and Head of RBC’s European Healthcare equity research team. He has covered the European healthcare space for over eight years at both RBC and Investec. Nick started his career at Lloyd’s Pharmacy, registering as a pharmacist before joining GlaxoSmithKline (GSK). At GSK Nick worked within the Group’s R&D, UK Commercial Operations and Global Manufacturing & Supply Strategy finance teams where he trained as an accountant. Nick is a qualified accountant (ACMA) and a qualified pharmacist having completed his Masters degree in Pharmacy, Medicinal Chemistry, Pharmaceuticals, Biology and Maths from Aston University. Peter Allen, Chairman of Clinigen, said: “On behalf of the Board and everyone at Clinigen, I would like to thank Martin for his substantial contribution over the last three and a half years. During which time Clinigen has undergone a period of rapid change and development including the acquisitions and integration of Idis, Link, Quantum and CSM, plus a number of products. We wish him every success for the future.” Shaun Chilton, Group Chief Executive Officer of Clinigen, added: “Nick brings considerable pharmacy and pharmaceutical experience as well as financial expertise, both as an accountant and from working in the financial markets. He has a deep knowledge and insight of our business through his research and analysis of Clinigen since its IPO in 2012. He will be a key addition to the executive management team.” The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Nicholas Patrick Keher, aged 36 years, is not currently a director of any other companies. There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies. |
| - ENDS - |
| Contact details | |
| Clinigen Group plc Numis Securities Limited RBC Capital Markets – Joint Broker Instinctif Partners | Tel: +44 (0) 1283 495010 Tel: +44 (0) 20 7260 1000 Tel: +44 (0) 20 7653 4000 Tel: +44 (0) 20 7457 2020 |
| Notes To Editors About Clinigen Group Clinical Trial Services Unlicensed Medicines Commercial Medicines The Group also has an ‘unlicensed to licensed’ strategy, where it looks to take unlicensed medicines with commercial potential and licences them, helping to address unmet medical need and allowing the Group to capitalise on its market-leading positions. For more information on Clinigen, please visit www.clinigengroup.com |
